FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Arie Belldegrun

Research Profile

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Nils Kroeger; P Nagesh Rao; Joseph Riss; Geoffrey A Sonn; Arie S Belldegrun; Frédéric D Birkhäuser; Karim Chamie; Fairooz Kabbinavar; Tobias Klatte; Allan J Pantuck
Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.
Frédéric D Birkhäuser; Gadisetti V R Chandramouli; Thinle Chodon; Fairooz F Kabbinavar; Richard C Koya; Nils Kroeger; Gang Li; Xuyang Lu; William H McBride; Ewa D Micewicz; Caleb Neufeld; Allan J Pantuck; Edward N Rampersaud; Antoni Ribas; Mohammad Atefi; Arie S Belldegrun; Jonathan W Said; Joseph Riss
Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.
Tobias Klatte; Nils Kroeger; Joshua E Logan; Edward N Rampersaud; P Nagesh Rao; Joseph Riss; Geoffrey Sonn; Arie S Belldegrun; Frédéric D Birkhäuser; Fairooz Kabbinavar; Allan J Pantuck
Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Arie Belldegrun (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Nils Kroeger; P Nagesh Rao; Joseph Riss; Geoffrey A Sonn; Arie S Belldegrun; Frédéric D Birkhäuser; Karim Chamie; Fairooz Kabbinavar; Tobias Klatte; Allan J Pantuck
Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.
Cancer 2013;119(8):1547-54.
2013: Frédéric D Birkhäuser; Gadisetti V R Chandramouli; Thinle Chodon; Fairooz F Kabbinavar; Richard C Koya; Nils Kroeger; Gang Li; Xuyang Lu; William H McBride; Ewa D Micewicz; Caleb Neufeld; Allan J Pantuck; Edward N Rampersaud; Antoni Ribas; Mohammad Atefi; Arie S Belldegrun; Jonathan W Said; Joseph Riss
Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2013;36(2):102-11.
2012: Tobias Klatte; Nils Kroeger; Joshua E Logan; Edward N Rampersaud; P Nagesh Rao; Joseph Riss; Geoffrey Sonn; Arie S Belldegrun; Frédéric D Birkhäuser; Fairooz Kabbinavar; Allan J Pantuck
Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma.
Cancer 2012;118(23):5777-82.
2012: Brian Shuch; Eric Treat; Srinivas Vourganti; Gennady Bratslavsky; Brandon Castor; David Finley; W Marston Linehan; Allan J Pantuck; Jonathan W Said; Joanna Shih; Arie S Belldegrun
Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma.
BJU international 2012;109(11):1600-6.
2012: Nils Kroeger; John T Leppert; Arie S Belldegrun; Frédéric D Birkhäuser; Fairooz Kabbinavar; Tobias Klatte; Edward N Rampersaud; P Nagesh Rao; David B Seligson; Nazy Zomorodian; Allan J Pantuck
Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma.
European urology 2012;61(5):888-95.
2012: Nils Kroeger; Edward N Rampersaud; David B Seligson; Nazy Zomorodian; Arie S Belldegrun; Frédéric D Birkhäuser; Fairooz Kabbinavar; Tobias Klatte; Allan J Pantuck
Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival.
Cancer 2012;118(7):1795-802.
2012: Joshua E Logan; Allan J Pantuck; Edward N Rampersaud; Dennis J Slamon; Geoffrey A Sonn; Arie S Belldegrun; Karim Chamie; Fairooz Kabbinavar
Systemic therapy for metastatic renal cell carcinoma: a review and update.
Reviews in urology 2012;14(3-4):65-78.
2011: Steven C Sauk; Nagesh P Rao; Arie S Belldegrun; Margaret S Hsu; David S K Lu; Daniel J A Margolis; Allan J Pantuck; Steven S Raman
Clear cell renal cell carcinoma: multiphasic multidetector CT imaging features help predict genetic karyotypes.
Radiology 2011;261(3):854-62.
2011: David S Finley; Gretchen Galliano; Robin A Jeffries; Fairooz Kabbinavar; Clara Magyar; Abdelmonem A Afifi; Arie S Belldegrun; Brandon Castor; Ardavan Sadaat; Jonathan W Said; Brian Shuch; Allan J Pantuck
The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma.
The Journal of urology 2011;186(6):2168-74.
2011: Brian Shuch; Arie S Belldegrun; David S Finley; Allan J Pantuck; Frederic Pouliot; Jonathan W Said; Chris Saigal
Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance.
BJU international 2011;108(3):343-8.
2011: David S Finley; Arie S Belldegrun
Salvage cryotherapy for radiation-recurrent prostate cancer: outcomes and complications.
Current urology reports 2011;12(3):209-15.
2011: Brian Shuch; Paul L Crispen; Bradley C Leibovich; Jeff C Larochelle; Frederic Pouliot; Allan J Pantuck; Weiqing Liu; Maxime Crepel; Anne Schuckman; Jerome Rigaud; Oliver Bouchot; Jean-Jacques Patard; Donald Skinner; Arie S Belldegrun; Michael L Blute
Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality?
BJU international 2011;107(5):724-8.
2011: Edward N Rampersaud; Arie S Belldegrun
Words of Wisdom. Re: randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
European urology 2011;59(2):301-2.
2011: David S Finley; Frederic Pouliot; Arnold I Chin; Brian Shuch; Alan J Pantuck; Arie S Belldegrun; Jean B deKernion
Immunological therapy in urological malignancy: novel combination strategies.
International journal of urology : official journal of the Japanese Urological Association 2011;18(2):94-101.
2011: David S Finley; Allan J Pantuck; Arie S Belldegrun
Tumor biology and prognostic factors in renal cell carcinoma.
The oncologist 2011;16 Suppl 2():4-13.
2011: David S Finley; Frederic Pouliot; Brian Shuch; Arnold Chin; Alan Pantuck; Jean B deKernion; Arie S Belldegrun
Ultrasound-based combination therapy: potential in urologic cancer.
Expert review of anticancer therapy 2011;11(1):107-13.
2011: Tobias Klatte; Jonathan W Said; David B Seligson; P Nagesh Rao; Michela de Martino; Brian Shuch; Nazy Zomorodian; Fairooz Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features.
The Journal of urology 2011;185(1):30-5.
2010: Frédéric Pouliot; Brian Shuch; Jeffrey C La Rochelle; Allan J Pantuck; Arie S Belldegrun
Contemporary management of renal tumors with venous tumor thrombus.
The Journal of urology 2010;184(3):833-41; quiz 1235.
2010: Amnon Zisman; Jean-Jacques Patard; Orit Raz; Tobias Klatte; Miki Haifler; Sonia Mendlovic; Judith Sandbank; Arie S Belldegrun; Arie Lindner; Dan Leibovici; Allan J Pantuck
Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings--a multicenter survey.
Urology 2010;76(3):541-6.
2010: Tobias Klatte; Mesut Remzi; Richard Zigeuner; Sebastian Mannweiler; Jonathan W Said; Fairooz F Kabbinavar; Andrea Haitel; Matthias Waldert; Michela de Martino; Michael Marberger; Arie S Belldegrun; Allan J Pantuck
Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma.
The Journal of urology 2010;184(1):53-8.
2010: Tobias Klatte; David B Seligson; Jian Yu Rao; Hong Yu; Michela de Martino; Isla Garraway; Steven G Wong; Arie S Belldegrun; Allan J Pantuck
Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome.
The Journal of urology 2010;183(6):2403-8.
2010: Tobias Klatte; Christine Anterasian; Jonathan W Said; Michela de Martino; Fairooz Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma.
The Journal of urology 2010;183(6):2143-7.
2010: Jean-Christophe Bernhard; Allan J Pantuck; Hervé Wallerand; Maxime Crepel; Jean-Marie Ferrière; Laurent Bellec; Sylvie Maurice-Tison; Grégoire Robert; Baptiste Albouy; Gilles Pasticier; Michel Soulie; David Lopes; Bertrand Lacroix; Karim Bensalah; Christian Pfister; Rodolphe Thuret; Jacques Tostain; Alexandre de la Taille; Laurent Salomon; Clément Abbou; Marc Colombel; Arie S Belldegrun; Jean-Jacques Patard
Predictive factors for ipsilateral recurrence after nephron-sparing surgery in renal cell carcinoma.
European urology 2010;57(6):1080-6.
2010: Pierre Bigot; J-C Bernhard; Maxime Crepel; Karim Bensalah; A-R Azzouzi; Alexandre de la Taille; Laurent Salomon; Jacques Tostain; Vincenzo Ficarra; Allan J Pantuck; Arie S Belldegrun; A Méjean; J-M Ferrière; Christian Pfister; Baptiste Albouy; Marc Colombel; L Zini; A Villers; F Montorsi; S Shariat; Nathalie Rioux-Leclercq; Jean-Jacques Patard
[How radical nephrectomy compares to partial nephrectomy for the treatment of pT1a papillary renal cell carcinomas?].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2010;20(5):350-5.
2010: Alberto Breda; Eric G Treat; Leah Haft-Candell; John T Leppert; Jonathan D Harper; Jonathan Said; Steven Raman; Robert B Smith; Arie S Belldegrun; Peter Schulam
Comparison of accuracy of 14-, 18- and 20-G needles in ex-vivo renal mass biopsy: a prospective, blinded study.
BJU international 2010;105(7):940-5.
2010: David S Finley; Frederic Pouliot; David C Miller; Arie S Belldegrun
Primary and salvage cryotherapy for prostate cancer.
The Urologic clinics of North America 2010;37(1):67-82, Table of Contents.
2010: Brian Shuch; Jonathan Said; Jeffrey C La Rochelle; Ying Zhou; Gang Li; Tobias Klatte; Frederic Pouliot; Fairooz Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy.
Cancer 2010;116(3):616-24.
2009: Pierre I Karakiewicz; Nazareno Suardi; umberto capitanio; Hendrik Isbarn; Claudio Jeldres; Paul Perrotte; Maxine Sun; Vincenzo Ficarra; Richard Zigeuner; Jacques Tostain; Arnaud Mejean; Luca Cindolo; Allan J Pantuck; Arie S Belldegrun; Laurent Zini; Alexandre de la Taille; Denis Chautard; Jean-Luc Descotes; Shahrokh F Shariat; Antoine Valeri; Peter F A Mulders; Hervé Lang; Eric Lechevallier; Jean-Jacques Patard
Conditional survival predictions after nephrectomy for renal cell carcinoma.
The Journal of urology 2009;182(6):2607-12.
2009: Brian Shuch; Jonathan Said; Jeffrey C La Rochelle; Ying Zhou; Gang Li; Tobias Klatte; Fairooz F Kabbinaavar; Allan J Pantuck; Arie S Belldegrun
Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable?
The Journal of urology 2009;182(5):2164-71.
2009: Michela de Martino; Tobias Klatte; David B Seligson; Jeffrey C La Rochelle; Brian Shuch; Randy Caliliw; Z Li; Fairooz Kabbinavar; Allan J Pantuck; Arie S Belldegrun
CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.
The Journal of urology 2009;182(2):728-34.
2009: Tobias Klatte; Jonathan W Said; Michela de Martino; Jeffrey C La Rochelle; Brian Shuch; Jian Yu Rao; George V Thomas; Fairooz Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification.
The Journal of urology 2009;181(4):1558-64; discussion 1563-4.
2009: Tobias Klatte; David B Seligson; Jian Yu Rao; Hong Yu; Michela de Martino; Kelly Kawaoka; Steven G Wong; Arie S Belldegrun; Allan J Pantuck
Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.
Cancer 2009;115(7):1448-58.
2009: Tobias Klatte; David B Seligson; Jeffrey C La Rochelle; Brian Shuch; Jonathan W Said; Stephen B Riggs; Nazy Zomorodian; Fairooz Kabbinavar; Allan J Pantuck; Arie S Belldegrun
Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009;18(3):894-900.
2009: Tobias Klatte; Allan J Pantuck; Jonathan W Said; David B Seligson; Nagesh P Rao; Jeffrey C La Rochelle; Brian Shuch; Amnon Zisman; Fairooz Kabbinavar; Arie S Belldegrun
Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1162-9.
2009: Tobias Klatte; P Nagesh Rao; Michela de Martino; Jeffrey C La Rochelle; Brian Shuch; Nazy Zomorodian; Jonathan Said; Fairooz Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(5):746-53.
2009: Brian Shuch; Jeffrey C La Rochelle; Thomas Onyia; Cristianna Vallera; Dan Margulis; Allan J Pantuck; Robert B Smith; Arie S Belldegrun
Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience.
The Journal of urology 2009;181(2):492-8; discussion 498-9.
2009: Michael K Brawer; Stacy Loeb; Alan W Partin; Naoki Yoshimura; Michael B Chancellor; Claus G Roehrborn; Dean G Assimos; J Curtis Nickel; B Shuch; F Pouliot; Arie S Belldegrun; Ellen Shapiro
Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.
Reviews in urology 2009;11(2):82-107.
2008: Arie S Belldegrun; Tobias Klatte; Brian Shuch; Jeffrey C La Rochelle; David C Miller; Jonathan W Said; Stephen B Riggs; Nazy Zomorodian; Fairooz Kabbinavar; Jean B deKernion; Allan J Pantuck
Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.
Cancer 2008;113(9):2457-63.
2008: Karim Bensalah; Allan J Pantuck; Maxime Crepel; Grégory Verhoest; Arnaud Méjean; Antoine Valéri; Vincenzo Ficarra; Christian Pfister; Jean-Marie Ferrière; Michel Soulié; Luca Cindolo; Alexandre de la Taille; Jacques Tostain; Denis Chautard; Luigi Schips; Richard Zigeuner; Claude C Abbou; Bernard Lobel; Laurent Salomon; Eric Lechevallier; Jean-Luc Descotes; François Guillé; Marc Colombel; Arie S Belldegrun; Jean-Jacques Patard
Prognostic variables to predict cancer-related death in incidental renal tumours.
BJU international 2008;102(10):1376-80.
2008: Tobias Klatte; Ken-Ryu Han; Jonathan W Said; Malte Böhm; Ernst Peter Allhoff; Fairooz Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Pathobiology and prognosis of chromophobe renal cell carcinoma.
Urologic oncology 2008;26(6):604-9.
2008: Brian Shuch; Jeffrey C La Rochelle; Tobias Klatte; Stephen B Riggs; Weiqing Liu; Fairooz Kabbinavar; Allan J Pantuck; Arie S Belldegrun
Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival.
Cancer 2008;113(7):1641-8.
2008: Brian Shuch; Jeffrey C La Rochelle; Jon Wu; Tobias Klatte; Stephen B Riggs; Fairooz Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.
Cancer 2008;113(6):1324-31.
2008: Stephen B Riggs; Jeffrey C La Rochelle; Arie S Belldegrun
Partial nephrectomy: a contemporary review regarding outcomes and different techniques.
Cancer journal (Sudbury, Mass.) 2008;14(5):302-7.
2008: Tobias Klatte; John S Lam; Brian Shuch; Arie S Belldegrun; Allan J Pantuck
Surveillance for renal cell carcinoma: why and how? When and how often?
Urologic oncology 2008;26(5):550-4.
2008: Brian Shuch; Jeffrey C La Rochelle; Allan J Pantuck; Arie S Belldegrun
The staging of renal cell carcinoma.
Current opinion in urology 2008;18(5):455-61.
2008: Brian Shuch; Stephen B Riggs; Jeffrey C La Rochelle; Fairooz Kabbinavar; Raffi Avakian; Allan J Pantuck; Jean-Jacques Patard; Arie S Belldegrun
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
BJU international 2008;102(6):692-6.
2008: Jean-Jacques Patard; Patricia Fergelot; Pierre I Karakiewicz; Tobias Klatte; Quoc-Dien Trinh; Nathalie Rioux-Leclercq; Jonathan W Said; Arie S Belldegrun; Allan J Pantuck
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma.
International journal of cancer. Journal international du cancer 2008;123(2):395-400.
2008: Tobias Klatte; Arie S Belldegrun; Allan J Pantuck
The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder.
BJU international 2008;101 Suppl 4():45-8.
2008: Brian Shuch; Zhenhua Li; Arie S Belldegrun
Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies.
BJU international 2008;101 Suppl 4():25-30.
2008: Arie S Belldegrun; Paul Bevan
Carbonic anhydrase IX: role in diagnosis prognosis and cancer therapy. Introduction.
BJU international 2008;101 Suppl 4():1.
2008: Tobias Klatte; Jean-Jacques Patard; Michela de Martino; Karim Bensalah; Gregory Verhoest; Alexandre de la Taille; Clément-Claude Abbou; Ernst Peter Allhoff; Giuseppe Carrieri; Stephen B Riggs; Fairooz Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas.
The Journal of urology 2008;179(5):1719-26.
2008: Jon Jones; Hasan H Otu; Franck Grall; Dimitrios Spentzos; Handan Can; Manuel Aivado; Arie S Belldegrun; Allan J Pantuck; Towia Libermann
Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer.
The Journal of urology 2008;179(2):730-6.
2008: Jeffrey C La Rochelle; Arie S Belldegrun
Which pathological features of renal cell carcinoma have the greatest prognostic value?
Nature clinical practice. Urology 2008;5(2):74-5.
2008: Louis M Weiner; Arie S Belldegrun; Jeffrey Crawford; Anthony W Tolcher; Pamela Lockbaum; Rosalin H Arends; Lynn Navale; Rafael G Amado; Gisela Schwab; Robert A Figlin
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):502-8.
2008: Alberto Breda; John S Lam; Stephen B Riggs; John T Leppert; Dorina Gui; Jonathan W Said; Peter Schulam; Arie S Belldegrun
In vivo efficacy of laparoscopic assisted percutaneous renal cryotherapy: evidence based guidelines for the practicing urologist.
The Journal of urology 2008;179(1):333-7.
2008: Tobias Klatte; David Seligson; John T Leppert; Stephen B Riggs; Hong Yu; Nazy Zomorodian; Fairooz Kabbinavar; Robert M Strieter; Arie S Belldegrun; Allan J Pantuck
The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma.
The Journal of urology 2008;179(1):61-6.
2007: Tobias Klatte; David Seligson; Stephen B Riggs; John T Leppert; Maria K Berkman; Mark D Kleid; Hong Yu; Fairooz Kabbinavar; Allan J Pantuck; Arie S Belldegrun
Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(24):7388-93.
2007: Georg C Hutterer; Jean-Jacques Patard; Marc Colombel; Arie S Belldegrun; Christian Pfister; Francois Guille; Walter Artibani; Francesco Montorsi; Allan J Pantuck; Pierre I Karakiewicz
Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma.
Cancer 2007;110(11):2428-33.
2007: Allan J Pantuck; Jack Baniel; Ziya Kirkali; Tobias Klatte; Nazy Zomorodian; Ofer Yossepowitch; Arie S Belldegrun
A novel resectoscope for transurethral resection of bladder tumors and the prostate.
The Journal of urology 2007;178(6):2331-6; discussion 2336.
2007: Stephen B Riggs; Tobias Klatte; Arie S Belldegrun
Update on partial nephrectomy and novel techniques.
Urologic oncology 2007;25(6):520-2.
2007: Pierre I Karakiewicz; Quoc-Dien Trinh; John S Lam; Jacques Tostain; Allan J Pantuck; Arie S Belldegrun; Jean-Jacques Patard
Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality.
European urology 2007;52(5):1428-36.
2007: Pierre I Karakiewicz; Georg C Hutterer; Quoc-Dien Trinh; Allan J Pantuck; Tobias Klatte; John S Lam; Francois Guille; Alexandre de la Taille; Giacomo Novara; Jacques Tostain; Luca Cindolo; Vincenzo Ficarra; Luigi Schips; Richard Zigeuner; Peter F A Mulders; Denis Chautard; Eric Lechevallier; Antoine Valeri; Jean-Luc Descotes; Herve Lang; Michel Soulie; Jean-Marie Ferriere; Christian Pfister; Arnaud Mejean; Arie S Belldegrun; Jean-Jacques Patard
Unclassified renal cell carcinoma: an analysis of 85 cases.
BJU international 2007;100(4):802-8.
2007: Tobias Klatte; Allan J Pantuck; Stephen B Riggs; Mark D Kleid; Brian Shuch; Nazy Zomorodian; Fairooz Kabbinavar; Arie S Belldegrun
Prognostic factors for renal cell carcinoma with tumor thrombus extension.
The Journal of urology 2007;178(4 Pt 1):1189-95; discussion 1195.
2007: Tobias Klatte; Jonathan W Said; Arie S Belldegrun; Allan J Pantuck
Differential diagnosis of hypercalcemia in renal malignancy.
Urology 2007;70(1):179.e7-8.
2007: Tobias Klatte; Jean-Jacques Patard; Rakhee H Goel; Mark D Kleid; Francois Guille; Bernard Lobel; Claude C Abbou; Alexandre de la Taille; Jacques Tostain; Luca Cindolo; Vincenzo Altieri; Vincenzo Ficarra; Walter Artibani; Tommaso Prayer-Galetti; Ernst Peter Allhoff; Luigi Schips; Richard Zigeuner; Robert A Figlin; Fairooz Kabbinavar; Allan J Pantuck; Arie S Belldegrun; John S Lam
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience.
The Journal of urology 2007;178(1):35-40; discussion 40.
2007: Tobias Klatte; Heiko Wunderlich; Jean-Jacques Patard; Mark D Kleid; John S Lam; Kerstin Junker; Jörg Schubert; Malte Böhm; Ernst Peter Allhoff; Fairooz Kabbinavar; Maxime Crepel; Luca Cindolo; Alexandre de la Taille; Jacques Tostain; Arnaud Mejean; Michel Soulie; Laurent Bellec; Jean Christophe Bernhard; Jean-Marie Ferriere; Christian Pfister; Baptiste Albouy; Marc Colombel; Amnon Zisman; Arie S Belldegrun; Allan J Pantuck
Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience.
BJU international 2007;100(1):21-5.
2007: John S Lam; Tobias Klatte; Jean-Jacques Patard; Rakhee H Goel; François Guillè; Bernard Lobel; Claude C Abbou; Alexandre de la Taille; Jacques Tostain; Luca Cindolo; Vincenzo Altieri; Vincenzo Ficarra; Walter Artibani; Tommaso Prayer-Galetti; Luigi Schips; Richard Zigeuner; Allan J Pantuck; Robert A Figlin; Arie S Belldegrun
Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience.
European urology 2007;52(1):155-62.
2007: Jean-Jacques Patard; Allan J Pantuck; Maxime Crepel; John S Lam; Laurent Bellec; Baptiste Albouy; David Lopes; Jean-Christophe Bernhard; François Guillé; Bertrand Lacroix; Alexandre de la Taille; Laurent Salomon; Christian Pfister; Michel Soulié; Jacques Tostain; Jean-Marie Ferriere; Claude C Abbou; Marc Colombel; Arie S Belldegrun
Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication.
European urology 2007;52(1):148-54.
2007: Tobias Klatte; Jean-Jacques Patard; Heiko Wunderlich; Rakhee H Goel; John S Lam; Kerstin Junker; Jörg Schubert; Malte Böhm; Ernst Peter Allhoff; Fairooz Kabbinavar; Maxime Crepel; Luca Cindolo; Alexandre de la Taille; Jacques Tostain; Arnaud Mejean; Michel Soulie; Laurent Bellec; Jean Christophe Bernhard; Jean-Marie Ferriere; Christian Pfister; Baptiste Albouy; Marc Colombel; Amnon Zisman; Arie S Belldegrun; Allan J Pantuck
Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval.
The Journal of urology 2007;177(6):2081-6; discussion 2086-7.
2007: Allan J Pantuck; David Seligson; Tobias Klatte; Hong Yu; John T Leppert; Laurence Moore; Timothy O'Toole; Jay Gibbons; Arie S Belldegrun; Robert A Figlin
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
Cancer 2007;109(11):2257-67.
2007: Karen Reckamp; Robert A Figlin; Nancy Moldawer; Allan J Pantuck; Arie S Belldegrun; Marie D Burdick; Robert M Strieter
Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(4):417-24.
2007: John T Leppert; Allan J Pantuck; Robert A Figlin; Arie S Belldegrun
The role of molecular markers in the staging of renal cell carcinoma.
BJU international 2007;99(5 Pt B):1208-11.
2007: Tobias Klatte; Jinsoo Chung; John T Leppert; John S Lam; Allan J Pantuck; Robert A Figlin; Arie S Belldegrun
Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma.
BJU international 2007;99(4):821-4.
2007: John S Lam; Allan J Pantuck; Arie S Belldegrun; Robert A Figlin
Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 2):703s-708s.
2007: Allan J Pantuck; Arie S Belldegrun; Robert A Figlin
Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 2):693s-696s.
2007: Tobias Klatte; Allan J Pantuck; Mark D Kleid; Arie S Belldegrun
Understanding the natural biology of kidney cancer: implications for targeted cancer therapy.
Reviews in urology 2007;9(2):47-56.
2007: Allan J Pantuck; Nazy Zomorodian; Arie S Belldegrun
Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy.
Current urology reports 2007;8(1):3-4.
2007: Robert H Weiss; Alexander D Borowsky; David Seligson; Pei-Yin Lin; Lisa Dillard-Telm; Arie S Belldegrun; Robert A Figlin; Allan D Pantuck
p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches.
The Journal of urology 2007;177(1):63-8; discussion 68-9.
2006: John S Lam; Alberto Breda; Arie S Belldegrun; Robert A Figlin
Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(35):5565-75.
2006: Oleg Shvarts; Nicolette K Janzen; John S Lam; John T Leppert; Randy Caliliw; Robert A Figlin; Arie S Belldegrun; Gang Zeng
RENCA/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma.
Urology 2006;68(5):1132-8.
2006: Allan J Pantuck; George Thomas; Arie S Belldegrun; Robert A Figlin
Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications.
Seminars in oncology 2006;33(5):607-13.
2006: Brian M Shuch; John S Lam; Arie S Belldegrun; Robert A Figlin
Prognostic factors in renal cell carcinoma.
Seminars in oncology 2006;33(5):563-75.
2006: Gang Zeng; Michael E Aldridge; Xiaoli Tian; Daniel Seiler; Xiaolong Zhang; Yusheng Jin; Jianyu Rao; Weidong Li; Dequan Chen; Marlyn P Langford; Chris Duggan; Arie S Belldegrun; Steven M Dubinett
Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(6):3582-9.
2006: John S Lam; David Seligson; Hong Yu; Ai Li; Mervi Eeva; Allan J Pantuck; Gang Zeng; Steve Horvath; Arie S Belldegrun
Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score.
BJU international 2006;98(2):445-51.
2006: John S Lam; Arie S Belldegrun; Allan J Pantuck
Long-term outcomes of the surgical management of renal cell carcinoma.
World journal of urology 2006;24(3):255-66.
2006: John T Leppert; John S Lam; Anthony W Butch; Arie S Belldegrun
The sensitivity of testosterone immunoassays and their role in monitoring antiandrogen therapy.
Urologic oncology 2006;24(4):277-8.
2006: John S Lam; Arie S Belldegrun; Robert A Figlin
Adjuvant treatment for renal cell carcinoma.
Expert opinion on pharmacotherapy 2006;7(6):705-20.
2006: John T Leppert; Oleg Shvarts; Kelly Kawaoka; Ron Lieberman; Arie S Belldegrun; Allan J Pantuck
Prevention of bladder cancer: a review.
European urology 2006;49(2):226-34.
2006: Arnold I Chin; John S Lam; Robert A Figlin; Arie S Belldegrun
Surveillance strategies for renal cell carcinoma patients following nephrectomy.
Reviews in urology 2006;8(1):1-7.
2006: Brian Shuch; John S Lam; Arie S Belldegrun
Open partial nephrectomy for the treatment of renal cell carcinoma.
Current urology reports 2006;7(1):31-8.
2006: Allan J Pantuck; Nazy Zomorodian; Arie S Belldegrun
Phase-II Study of pomegranate juice for men with prostate cancer and increasing PSA.
Current urology reports 2006;7(1):7.
2006: John S Lam; John T Leppert; Sreenivas N Vemulapalli; Oleg Shvarts; Arie S Belldegrun
Secondary hormonal therapy for advanced prostate cancer.
The Journal of urology 2006;175(1):27-34.
2005: Dhiren S Dave; John S Lam; John T Leppert; Arie S Belldegrun
Open surgical management of renal cell carcinoma in the era of minimally invasive kidney surgery.
BJU international 2005;96(9):1268-74.
2005: Gerhardt Attard; Arie S Belldegrun; Johann S de Bono
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
BJU international 2005;96(9):1241-6.
2005: John S Lam; John T Leppert; Robert A Figlin; Arie S Belldegrun
Role of molecular markers in the diagnosis and therapy of renal cell carcinoma.
Urology 2005;66(5 Suppl):1-9.
2005: John T Leppert; John S Lam; Arie S Belldegrun
Predicting response to interleukin-2 therapy among patients with renal cell carcinoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(5):427-9.
2005: John S Lam; John T Leppert; Arie S Belldegrun; Robert A Figlin
Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options.
BJU international 2005;96(4):483-8.
2005: John T Leppert; John S Lam; Allan J Pantuck; Robert A Figlin; Arie S Belldegrun
Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma.
BJU international 2005;96(3):281-5.
2005: John S Lam; Oleg Shvarts; John T Leppert; Allan J Pantuck; Robert A Figlin; Arie S Belldegrun
Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system.
The Journal of urology 2005;174(2):466-72; discussion 472; quiz 801.
2005: John S Lam; John T Leppert; Arie S Belldegrun; Robert A Figlin
Novel approaches in the therapy of metastatic renal cell carcinoma.
World journal of urology 2005;23(3):202-12.
2005: John S Lam; Oleg Shvarts; Jonathan W Said; Allan J Pantuck; David Seligson; Michael E Aldridge; Matthew H T Bui; Xueli Liu; Steve Horvath; Robert A Figlin; Arie S Belldegrun
Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
Cancer 2005;103(12):2517-25.
2005: John S Lam; Oleg Shvarts; John T Leppert; Robert A Figlin; Arie S Belldegrun
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
The Journal of urology 2005;173(6):1853-62.
2005: Nicolette K Janzen; Ken-Ryu Han; Kent T Perry; Jonathan W Said; Peter Schulam; Arie S Belldegrun
Feasibility of nerve-sparing prostate cryosurgery: applications and limitations in a canine model.
Journal of endourology / Endourological Society 2005;19(4):520-5.
2005: Hyung L Kim; David Seligson; Xueli Liu; Nicolette K Janzen; Matthew H T Bui; Hong Yu; Tao Shi; Arie S Belldegrun; Steve Horvath; Robert A Figlin
Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma.
The Journal of urology 2005;173(5):1496-501.
2005: Jean-Jacques Patard; Emmanuelle Leray; Nathalie Rioux-Leclercq; Luca Cindolo; Vincenzo Ficarra; Amnon Zisman; Alexandre de la Taille; Jacques Tostain; Walter Artibani; Claude C Abbou; Bernard Lobel; François Guillé; Dominique K Chopin; Peter F A Mulders; Christopher G Wood; David A Swanson; Robert A Figlin; Arie S Belldegrun; Allan J Pantuck
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2763-71.
2005: Nicolette K Janzen; Kent T Perry; Ken-Ryu Han; Blaine Kristo; Steven Raman; Jonathan W Said; Arie S Belldegrun; Peter Schulam
The effects of intentional cryoablation and radio frequency ablation of renal tissue involving the collecting system in a porcine model.
The Journal of urology 2005;173(4):1368-74.
2005: Tao Shi; David Seligson; Arie S Belldegrun; Aarno Palotie; Steve Horvath
Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005;18(4):547-57.
2005: Gang Zeng; Michael E Aldridge; Yu Wang; Allan J Pantuck; Allen Y Wang; Yue-xiang Liu; Yan Han; Yan-hua Yuan; Paul F Robbins; Steven M Dubinett; Jean B deKernion; Arie S Belldegrun
Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker.
International journal of cancer. Journal international du cancer 2005;114(2):268-73.
2005: Oleg Shvarts; John S Lam; Hyung L Kim; Arie S Belldegrun
Staging of renal cell carcinoma: current concepts.
BJU international 2005;95 Suppl 2():8-13.
2005: John S Lam; Allan J Pantuck; Arie S Belldegrun; Robert A Figlin
G250: a carbonic anhydrase IX monoclonal antibody.
Current oncology reports 2005;7(2):109-15.
2005: John S Lam; John T Leppert; Robert A Figlin; Arie S Belldegrun
Surveillance following radical or partial nephrectomy for renal cell carcinoma.
Current urology reports 2005;6(1):7-18.
2004: John S Lam; Arie S Belldegrun; Robert A Figlin
Advances in immune-based therapies of renal cell carcinoma.
Expert review of anticancer therapy 2004;4(6):1081-96.
2004: Jean-Jacques Patard; Frederick J Dorey; Luca Cindolo; Vincenzo Ficarra; Alexandre de la Taille; Jacques Tostain; Walter Artibani; Claude C Abbou; Bernard Lobel; Dominique K Chopin; Robert A Figlin; Arie S Belldegrun; Allan J Pantuck
Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors.
The Journal of urology 2004;172(6 Pt 1):2167-71.
2004: John S Lam; Arie S Belldegrun; Robert A Figlin
Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 2):6304S-9S.
2004: Ken-Ryu Han; Nicolette K Janzen; Valerie C McWhorter; Hyung L Kim; Allan J Pantuck; Amnon Zisman; Robert A Figlin; Frederick J Dorey; Jonathan W Said; Arie S Belldegrun
Cystic renal cell carcinoma: biology and clinical behavior.
Urologic oncology 2004;22(5):410-4.
2004: Hyung L Kim; David Seligson; Xueli Liu; Nicolette K Janzen; Matthew H T Bui; Hong Yu; Tao Shi; Robert A Figlin; Steve Horvath; Arie S Belldegrun
Using protein expressions to predict survival in clear cell renal carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(16):5464-71.
2004: Jean-Jacques Patard; Hyung L Kim; John S Lam; Frederick J Dorey; Allan J Pantuck; Amnon Zisman; Vincenzo Ficarra; Ken-Ryu Han; Luca Cindolo; Alexandre de la Taille; Jacques Tostain; Walter Artibani; Colin P N Dinney; Christopher G Wood; David A Swanson; Claude C Abbou; Bernard Lobel; Peter F A Mulders; Dominique K Chopin; Robert A Figlin; Arie S Belldegrun
Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(16):3316-22.
2004: Alvin Y Liu; Kristen D Brubaker; Young Ah Goo; Janna E Quinn; Sabine Kral; Carrie M Sorensen; Robert L Vessella; Arie S Belldegrun; Leroy Hood
Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines.
The Prostate 2004;60(2):98-108.
2004: Matthew H T Bui; Harri Visapaa; David Seligson; Hyung Kim; Ken-Ryu Han; Yunda Huang; Steve Horvath; Eric J Stanbridge; Aarno Palotie; Robert A Figlin; Arie S Belldegrun
Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma.
The Journal of urology 2004;171(6 Pt 1):2461-6.
2004: Jean-Jacques Patard; Oleg Shvarts; John S Lam; Allan J Pantuck; Hyung L Kim; Vincenzo Ficarra; Luca Cindolo; Ken-Ryu Han; Alexandre de la Taille; Jacques Tostain; Walter Artibani; Claude C Abbou; Bernard Lobel; Dominique K Chopin; Robert A Figlin; Peter F A Mulders; Arie S Belldegrun
Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience.
The Journal of urology 2004;171(6 Pt 1):2181-5, quiz 2435.
2004: Ken-Ryu Han; Hyung L Kim; Allan J Pantuck; Frederick J Dorey; Robert A Figlin; Arie S Belldegrun
Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma.
Urology 2004;63(5):841-6; discussion 846-7.
2004: Hyung L Kim; Ken-Ryu Han; Amnon Zisman; Robert A Figlin; Arie S Belldegrun
Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma.
The Journal of urology 2004;171(5):1810-3.
2004: Allan J Pantuck; Arndt van Ophoven; Barbara J Gitlitz; Cho-Lea Tso; Bruce Acres; Patrick Squiban; Michael E Ross; Arie S Belldegrun; Robert A Figlin
Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(3):240-53.
2004: David Seligson; Allan J Pantuck; Xueli Liu; Yunda Huang; Steve Horvath; Matthew H T Bui; Ken-Ryu Han; Adrian J L Correa; Mervi Eeva; Sheila Tze; Arie S Belldegrun; Robert A Figlin
Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(8):2659-69.
2004: Kenneth A Foon; Xiao-Dong Yang; Louis M Weiner; Arie S Belldegrun; Robert A Figlin; Jeffrey Crawford; Eric K Rowinsky; Janice P Dutcher; Nicholas J Vogelzang; Jared Gollub; John A Thompson; Garry Schwartz; Ronald M Bukowski; Lorin K Roskos; Gisela Schwab
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
International journal of radiation oncology, biology, physics 2004;58(3):984-90.
2004: Hideki Mukouyama; Nicolette K Janzen; Jose M Hernandez; John S Lam; Randy Caliliw; Allen Y Wang; Robert A Figlin; Arie S Belldegrun; Gang Zeng
Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(4):1421-9.
2004: Hyung L Kim; John S Lam; Arie S Belldegrun
The role of lymphadenectomy in renal cell carcinoma.
Current urology reports 2004;5(1):25-9.
2004: Oleg Shvarts; John Lam; Robert Figlin; Arie S Belldegrun
Heat shock-peptide complex vaccine as adjuvant therapy for high-risk patients with resected renal cell carcinoma.
Current urology reports 2004;5(1):11-2.
2004: John S Lam; Oleg Shvarts; Arie S Belldegrun
Kidney cancer management in 2004: an update for the practicing general urologist.
Current urology reports 2004;5(1):1-3.
2004: Hyung L Kim; Amnon Zisman; Ken-Ryu Han; Robert A Figlin; Arie S Belldegrun
Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different?
The Journal of urology 2004;171(2 Pt 1):588-91.
2004: John S Lam; Arie S Belldegrun
Salvage cryosurgery of the prostate after radiation failure.
Reviews in urology 2004;6 Suppl 4():S27-36.
2004: Oleg Shvarts; John Lam; Arie S Belldegrun
Report from the society of urologic oncology: highlights from the fourth annual meeting of the society of urologic oncology, december 5-6, 2003, bethesda, MD.
Reviews in urology 2004;6(4):193-9.
2004: Oleg Shvarts; Ken-Ryu Han; John S Lam; Arie S Belldegrun
Primary leiomyosarcoma of the inferior vena cava presenting as a renal mass.
Reviews in urology 2004;6(1):39-42.
2004: Ken-Ryu Han; Arie S Belldegrun
Third-generation cryosurgery for primary and recurrent prostate cancer.
BJU international 2004;93(1):14-8.
2003: Ken-Ryu Han; Ivar Bleumer; Allan J Pantuck; Hyung L Kim; Frederick J Dorey; Nicolette K Janzen; Amnon Zisman; Colin P N Dinney; Christopher G Wood; David A Swanson; Jonathan W Said; Robert A Figlin; Peter F A Mulders; Arie S Belldegrun
Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population.
The Journal of urology 2003;170(6 Pt 1):2221-4.
2003: Nicolette K Janzen; Hyung L Kim; Robert A Figlin; Arie S Belldegrun
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.
The Urologic clinics of North America 2003;30(4):843-52.
2003: Hyung L Kim; Arie S Belldegrun; Danielo G Freitas; Matthew H T Bui; Ken-Ryu Han; Frederick J Dorey; Robert A Figlin
Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis.
The Journal of urology 2003;170(5):1742-6.
2003: Allan J Pantuck; Gang Zeng; Arie S Belldegrun; Robert A Figlin
Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(13):4641-52.
2003: Ken-Ryu Han; Jeff K Cohen; Ralph J Miller; Allan J Pantuck; Danielo G Freitas; Carlos A Cuevas; Hyung L Kim; James Lugg; Stacy J Childs; Barry Shuman; Maury A Jayson; Neal D Shore; Yan Moore; Amnon Zisman; Joe Y Lee; Roland Ugarte; Lance A Mynderse; Torrence M Wilson; Susan D Sweat; Horst Zincke; Arie S Belldegrun
Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience.
The Journal of urology 2003;170(4 Pt 1):1126-30.
2003: Nicolette K Janzen; Sherelle Laifer-Narin; Ken-Ryu Han; Marc A Seltzer; Michael Albert Thomas; Allan J Pantuck; Arie S Belldegrun
Emerging technologies in uroradiologic imaging.
Urologic oncology 2003;21(5):317-26.
2003: Barbara J Gitlitz; Arie S Belldegrun; Amnon Zisman; Debby H Chao; Allan J Pantuck; Andreas Hinkel; Peter F A Mulders; Nancy Moldawer; Cho-Lea Tso; Robert A Figlin
A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(5):412-9.
2003: Ganesh S Palapattu; Allan J Pantuck; Frederick Dorey; Jonathan W Said; Robert A Figlin; Arie S Belldegrun
Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies.
The Journal of urology 2003;170(3):768-72; discussion 772.
2003: Amnon Zisman; Allan J Pantuck; Matthew H T Bui; Jonathan W Said; Randy Caliliw; Nagesh Rao; Peter Shintaku; Frank Berger; Sanjiv S Gambhir; Arie S Belldegrun
LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
Cancer research 2003;63(16):4952-9.
2003: Allan J Pantuck; Amnon Zisman; Frederick Dorey; Debby H Chao; Ken-Ryu Han; Jonathan Said; Barbara J Gitlitz; Arie S Belldegrun; Robert A Figlin
Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy.
Cancer 2003;97(12):2995-3002.
2003: Allan J Pantuck; Amnon Zisman; Frederick Dorey; Debby H Chao; Ken-Ryu Han; Jonathan Said; Barbara J Gitlitz; Robert A Figlin; Arie S Belldegrun
Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.
The Journal of urology 2003;169(6):2076-83.
2003: Stephen J Freedland; Allan J Pantuck; Sun H Paik; Amnon Zisman; Thomas G Graeber; David Eisenberg; william mcbride; David Nguyen; Cho-Lea Tso; Arie S Belldegrun
Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
The Prostate 2003;55(4):299-307.
2003: José M Hernández; Matthew H T Bui; Ken-Ryu Han; Hideki Mukouyama; Danielo G Freitas; David Nguyen; Randy Caliliw; Peter Shintaku; Sun H Paik; Cho-Lea Tso; Robert A Figlin; Arie S Belldegrun
Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1906-16.
2003: Stephen J Freedland; David Seligson; Alvin Y Liu; Allan J Pantuck; Sun H Paik; Steve Horvath; Jeffrey A Wieder; Amnon Zisman; David Nguyen; Cho-Lea Tso; Aarno V Palotie; Arie S Belldegrun
Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer.
The Prostate 2003;55(1):71-80.
2003: Amnon Zisman; Jeff A Wieder; Allan J Pantuck; Debby H Chao; Frederick Dorey; Jonathan W Said; Barbara J Gitlitz; Jean B deKernion; Robert A Figlin; Arie S Belldegrun
Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy.
The Journal of urology 2003;169(3):909-16.
2003: Ken-Ryu Han; Allan J Pantuck; Matthew H T Bui; Oleg Shvarts; Danielo G Freitas; Amnon Zisman; Bradley C Leibovich; Frederick J Dorey; Barbara J Gitlitz; Robert A Figlin; Arie S Belldegrun
Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma.
Urology 2003;61(2):314-9.
2003: Hyung L Kim; Arie S Belldegrun; Robert A Figlin
Immune gene therapy for kidney cancer: the search for a magic trigger.
Molecular therapy : the journal of the American Society of Gene Therapy 2003;7(2):153-4.
2003: Matthew H T Bui; David Seligson; Ken-Ryu Han; Allan J Pantuck; Frederick J Dorey; Yunda Huang; Steve Horvath; Bradley C Leibovich; Shefali Chopra; Shu-Yuan Liao; Eric J Stanbridge; Michael I Lerman; Aarno Palotie; Robert A Figlin; Arie S Belldegrun
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):802-11.
2003: Hyung L Kim; Allan J Pantuck; Nazy Zomorodian; Arie S Belldegrun
Monoclonal antibody (MAB) in patients with advanced cancer.
Current urology reports 2003;4(1):11-2.
2003: Ganesh S Palapattu; Hyung L Kim; Arie S Belldegrun
Advances in the Treatment of Genitourinary Cancer: Highlights from the 3rd Annual Meeting of the Society of Urologic Oncology, December 13-14, 2002, Washington, DC.
Reviews in urology 2003;5(4):232-4.
2003: Hyung L Kim; Ken-Ryu Han; Arie S Belldegrun
Late relapse of germ-cell tumor.
Reviews in urology 2003;5(3):207-8.
2003: Ganesh S Palapattu; Hyung L Kim; Arie S Belldegrun
Lymph node dissection in patients with kidney cancer: when is it indicated?
Reviews in urology 2003;5(3):196-9.
2003: Allan J Pantuck; Amnon Zisman; Arie S Belldegrun
Urologic oncology: extraordinary opportunities for discovery: highlights from the 2nd annual winter meeting of the society of urologic oncology december 1-2, 2001, bethesda, MD.
Reviews in urology 2003;5(1):26-8.
2003: Ken-Ryu Han; Allan J Pantuck; Arie S Belldegrun
Basic biology and clinical behavior of renal cell carcinoma.
Cancer treatment and research 2003;116():69-89.
2002: Amnon Zisman; Allan J Pantuck; Jeffery Wieder; Debby H Chao; Frederick Dorey; Jonathan W Said; Jean B deKernion; Robert A Figlin; Arie S Belldegrun
Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(23):4559-66.
2002: Frank Berger; Yu-Po Lee; Andreas M Loening; Arion F Chatziioannou; Stephen J Freedland; Richard M Leahy; Jay R Lieberman; Arie S Belldegrun; Charles L Sawyers; Sanjiv S Gambhir
Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease.
European journal of nuclear medicine and molecular imaging 2002;29(9):1225-36.
2002: Leonard S Marks; Robert S DiPaola; Peter Nelson; Sophie Chen; David Heber; Arie S Belldegrun; Franklin C Lowe; John Fan; Floyd E Leaders; Allan J Pantuck; Varro E Tyler
PC-SPES: herbal formulation for prostate cancer.
Urology 2002;60(3):369-75; discussion 376-7.
2002: Allan J Pantuck; Frank Berger; Amnon Zisman; David Nguyen; Cho-Lea Tso; Jamie Matherly; Sanjiv S Gambhir; Arie S Belldegrun
CL1-SR39: A noninvasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography.
The Journal of urology 2002;168(3):1193-8.
2002: Amnon Zisman; Allan J Pantuck; Debby H Chao; Jeff A Wieder; Frederick Dorey; Jonathan W Said; Jean B Kernion; Robert Figlin; Arie S Belldegrun
Renal cell carcinoma with tumor thrombus: is cytoreductive nephrectomy for advanced disease associated with an increased complication rate?
The Journal of urology 2002;168(3):962-7.
2002: Amnon Zisman; Debby H Chao; Allan J Pantuck; Hyun J Kim; Jeff A Wieder; Robert A Figlin; Jonathan W Said; Arie S Belldegrun
Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype.
The Journal of urology 2002;168(3):950-5.
2002: Oleg Shvarts; Ken-Ryu Han; Marc Seltzer; Allan J Pantuck; Arie S Belldegrun
Positron emission tomography in urologic oncology.
Cancer control : journal of the Moffitt Cancer Center 2002;9(4):335-42.
2002: Debby H Chao; Amnon Zisman; Allan J Pantuck; Stephen J Freedland; Jonathan W Said; Arie S Belldegrun
Changing concepts in the management of renal oncocytoma.
Urology 2002;59(5):635-42.
2002: Amnon Zisman; Allan J Pantuck; Frederick Dorey; Debby H Chao; Barbara J Gitlitz; Nancy Moldawer; Dana Lazarovici; Jean B deKernion; Robert A Figlin; Arie S Belldegrun
Mathematical model to predict individual survival for patients with renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1368-74.
2002: Nicolette K Janzen; Amnon Zisman; Allan J Pantuck; Kent Perry; Peter Schulam; Arie S Belldegrun
Minimally invasive ablative approaches in the treatment of renal cell carcinoma.
Current urology reports 2002;3(1):13-20.
2002: Ken-Ryu Han; Allan J Pantuck; Arie S Belldegrun
A randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2/interferon.
Current urology reports 2002;3(1):11-2.
2002: Ken-Ryu Han; Jeff A Wieder; Matthew Ht Bui; Arie S Belldegrun
Testicular microlithiasis, chemotherapy for stage I seminoma, and chemotherapy for advanced extragonadal germ cell tumors.
Reviews in urology 2002;4(4):200-2.
2002: Jeff Wieder; Jim Hu; Matt Bui; Steve Freedland; Arie S Belldegrun
Case scenario: 69-year-old male with left spermatic cord mass.
Reviews in urology 2002;4(3):153-6.
2002: Kent Perry; Amnon Zisman; Allan J Pantuck; Nicolette K Janzen; Peter Schulam; Arie S Belldegrun
Laparoscopic and percutaneous ablative techniques in the treatment of renal cell carcinoma.
Reviews in urology 2002;4(3):103-11.
2002: Ken-Ryu Han; Allan J Pantuck; Arie S Belldegrun; Jian-Yu Rao
Tumor markers for the early detection of bladder cancer.
Frontiers in bioscience : a journal and virtual library 2002;7():e19-26.
2002: Debby Chao; Amnon Zisman; Allan J Pantuck; Barbara J Gitlitz; Stephen J Freedland; Jonathan W Said; Robert A Figlin; Arie S Belldegrun
Collecting duct renal cell carcinoma: clinical study of a rare tumor.
The Journal of urology 2002;167(1):71-4.
2001: Amnon Zisman; Allan J Pantuck; J K Cohen; Arie S Belldegrun
Prostate cryoablation using direct transperineal placement of ultrathin probes through a 17-gauge brachytherapy template-technique and preliminary results.
Urology 2001;58(6):988-93.
2001: Amnon Zisman; C P Ng; Allan J Pantuck; B Bonavida; Arie S Belldegrun
Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(6):459-71.
2001: Allan J Pantuck; Amnon Zisman; Arie S Belldegrun
The changing natural history of renal cell carcinoma.
The Journal of urology 2001;166(5):1611-23.
2001: Amnon Zisman; Allan J Pantuck; D Chao; Frederick Dorey; Jonathan W Said; Barbara J Gitlitz; Jean B De Kernion; Robert A Figlin; Arie S Belldegrun
Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome.
The Journal of urology 2001;166(1):54-8.
2001: S J Freedland; Allan J Pantuck; J Weider; Amnon Zisman; Arie S Belldegrun
Immunotherapy of prostate cancer.
Current urology reports 2001;2(3):242-7.
2001: Amnon Zisman; Allan J Pantuck; Frederick Dorey; Jonathan W Said; Oleg Shvarts; D Quintana; Barbara J Gitlitz; Jean B deKernion; Robert A Figlin; Arie S Belldegrun
Improved prognostication of renal cell carcinoma using an integrated staging system.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1649-57.
2001: Barbara J Gitlitz; Robert A Figlin; Allan J Pantuck; Arie S Belldegrun
Dendritic cell-based immunotherapy of renal cell carcinoma.
Current urology reports 2001;2(1):46-52.
2000: B J Patel; Allan J Pantuck; Amnon Zisman; Ke-hung Tsui; Sun H Paik; Randy Caliliw; S Sheriff; Lily Wu; Jean B deKernion; Cho-Lea Tso; Arie S Belldegrun
CL1-GFP: an androgen independent metastatic tumor model for prostate cancer.
The Journal of urology 2000;164(4):1420-5.
2000: Allan J Pantuck; Amnon Zisman; Arie S Belldegrun
Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions.
World journal of urology 2000;18(2):143-7.
1999: Robert A Figlin; J A Thompson; R M Bukowski; N J Vogelzang; A C Novick; P Lange; G D Steinberg; Arie S Belldegrun
Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2521-9.
1999: Ganesh S Palapattu; J Naitoh; Arie S Belldegrun
Gene therapy for prostate cancer. New perspectives on an old problem.
The Urologic clinics of North America 1999;26(2):353-63, ix.
1999: J Naitoh; J Franklin; M A O'Donnell; Arie S Belldegrun
Interferon alpha for the treatment of superficial bladder cancer.
Advances in experimental medicine and biology 1999;462():371-86; discussion 387-92.
1998: Arie S Belldegrun; J R Franklin; M A O'Donnell; L G Gomella; E Klein; R Neri; U O Nseyo; T L Ratliff; R D Williams
Superficial bladder cancer: the role of interferon-alpha.
The Journal of urology 1998;159(6):1793-801.
1998: J Naitoh; Arie S Belldegrun
Interferon and kidney cancer: a promise unfulfilled?
The cancer journal from Scientific American 1998;4(3):155-6.
1997: Mark S Litwin; J T Fine; Frederick Dorey; Robert A Figlin; Arie S Belldegrun
Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study.
The Journal of urology 1997;157(5):1608-12.
1997: J Dannull; Arie S Belldegrun
Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen.
British journal of urology 1997;79 Suppl 1():97-103.
1997: Shen Pang; J Dannull; R Kaboo; Y Xie; Cho-Lea Tso; K Michel; Jean B deKernion; Arie S Belldegrun
Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen.
Cancer research 1997;57(3):495-9.